



US009408811B2

(12) **United States Patent**  
**Xu et al.**

(10) **Patent No.:** **US 9,408,811 B2**  
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **PHARMACEUTICAL COMPOSITION  
COMPRISING GUTTIFERONE F FOR THE  
TREATMENT OF PROSTATE CANCER**

(71) Applicant: **Hong Kong Baptist University**, Hong Kong (HK)

(72) Inventors: **Hongxi Xu**, Hong Kong (HK); **Xin Li**, Hong Kong (HK); **Hong Zhang**, Hong Kong (HK); **Yuanzhi Lao**, Hong Kong (HK); **Hongsheng Tan**, Hong Kong (HK); **Xiaoyu Wang**, Hong Kong (HK); **Kaixian Chen**, Hong Kong (HK); **Zhaoxiang Bian**, Hong Kong (HK); **Dajian Yang**, Hong Kong (HK); **Shilin Chen**, Hong Kong (HK); **Aiping Lu**, Hong Kong (HK); **Albert Sun Chi Chan**, Hong Kong (HK)

(73) Assignee: **Hong Kong Baptist University**, Hong Kong (HK)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 25 days.

(21) Appl. No.: **14/333,524**

(22) Filed: **Jul. 17, 2014**

(65) **Prior Publication Data**

US 2015/0025155 A1 Jan. 22, 2015

#### **Related U.S. Application Data**

(60) Provisional application No. 61/847,748, filed on Jul. 18, 2013.

(51) **Int. Cl.**

**C07C 33/38** (2006.01)

**C07C 35/23** (2006.01)

**A61K 31/122** (2006.01)

**A61K 36/38** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 31/122** (2013.01); **A61K 36/38** (2013.01); **A61K 2236/00** (2013.01)

(58) **Field of Classification Search**

CPC ..... C07C 33/38; C07C 35/23

USPC ..... 568/811, 820

See application file for complete search history.

(56) **References Cited**

#### **FOREIGN PATENT DOCUMENTS**

CN 101805352 A 8/2010  
KR 1005173 \* 1/2011

#### **OTHER PUBLICATIONS**

Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205.\*  
Hackam, et al. JAMA, 296(14), 2006, 1731-1732.\*  
Nguyen, et al. Tetrahedron Letters, 2012, 53(34), 4487-4493.\*  
R. Siegel et al., "Cancer statistics, 2013," CA Cancer J Clin, 63:11-30, 2013.

V. J. Gnanapragasam et al., "Androgen receptor signalling in the prostate," BJU International, 86, 1001-1013, 2000.

M. Papaioannou et al., "The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth," J Cell Mol Med, vol. 13, No. 8B, pp. 2210-2223, 2009.

V. Reutrakul et al., "Cytotoxic and anti-HIV-1 caged xanthenes from the resin and fruits of garcinia hanburyi," Planta Med, 73: 33-40, 2007.

Q. B. Han et al., "Caged garcinia xanthenes: development since 1937," Current Medicinal Chemistry, 16, 3775-3796, 2009.

Q. B. Han et al., "Cytotoxic Polyprenylated Xanthenes from the Resin of Garcinia hanburyi," Chem Pharm Bull, 54(2), 265-267, 2006.

V. Rukachaisirikul et al., "Antibacterial caged-tetraprenylated xanthenes from the stem bark of garcinia scorteichinii," Planta Med, 71: 165-170, 2005.

P. D. Sampath et al., "Mitigation of mitochondrial dysfunction and regulation of eNOS expression during experimental myocardial necrosis by alpha-mangostin, a xanthonic derivative from garcinia mangostana," Drug and Chemical Toxicology, 32(4): 344-352, 2009.


(Continued)

*Primary Examiner* — Douglas M Willis

(74) *Attorney, Agent, or Firm* — Ella Cheong Hong Kong; Sam T. Yip

(57) **ABSTRACT**

Prostate cancer is the most commonly diagnosed cancer in males and one of the leading causes of cancer death. Although treatment options have increased for some patients, overall progress has been modest. Thus, there is a great need to develop new treatments. This invention relates to a method for treating cancer comprising using an anti-cancer compound of formula (I):



More particularly, it relates to said anti-prostate cancer compound that can be isolated from *Garcinia esculenta* or chemically synthesized and its specific anticancer/antitumor activity. The invention has a specific application in treating human prostate cancer.

**8 Claims, 6 Drawing Sheets**